Nicotine Pharmacokinetic Profile of the CHTP 1.1 M

Not Applicable

Completed

• Conditions: Smoking
• Interventions: Other: CHTP 1.1 M; Other: mCC

• Registration Number: NCT02466412
• Lead Sponsor: Philip Morris Products S.A.

Brief Summary

The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile of nicotine (rate and amount of nicotine absorbed) after single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M), a potential Modified Risk Tobacco Product, compared to menthol cigarettes (mCC) in healthy smokers.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-05
• Study First Submitted: 2015-05-07
• Study First Submitted QC: 2015-06-08
• Study First Posted: 2015-06-09
• Primary Completion: 2015-08
• Study Completion: 2015-11
• Results First Submitted: 2017-02-17
• Results First Submitted QC: 2017-02-28
• Results First Posted: 2017-04-11
• Status Verified: 2020-05
• Last Update Submitted: 2020-05-05
• Last Update Posted: 2020-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• Subject is Japanese.
• Subject is at a minimum 23 years of age.
• Smoking, healthy subject as judged by the Investigator.
• Subject has smoked for at least the last 3 years
• Subject smoked at least 10 commercially available mCCs per day over the last 4 weeks.

Read More

Exclusion Criteria

• As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
• Subject has received medication within 14 days or within 5 half-lives of a drug (whichever is longer) which has an impact on CYP2A6 activity.
• Female subject is pregnant or breast feeding.
• Female subject does not agree to use an acceptable method of effective contraception.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
mCC then CHTP 1.1 M	CHTP 1.1 M	Each subject will follow the below study design: * Day -1 = Wash-out (1 day) * Day 1 = 1st intervention (single product use of mCC) * Day 2 = Wash-out * Day 3 = 2nd intervention (single product use of CHTP 1.1 M).
CHTP 1.1 M then mCC	CHTP 1.1 M	Each subject will follow the below study design: * Day -1 = Wash-out (1 day) * Day 1 = 1st intervention (single product use of CHTP 1.1 M) * Day 2 = Wash-out * Day 3 = 2nd intervention (single product use of mCC).
CHTP 1.1 M then mCC	mCC	Each subject will follow the below study design: * Day -1 = Wash-out (1 day) * Day 1 = 1st intervention (single product use of CHTP 1.1 M) * Day 2 = Wash-out * Day 3 = 2nd intervention (single product use of mCC).
mCC then CHTP 1.1 M	mCC	Each subject will follow the below study design: * Day -1 = Wash-out (1 day) * Day 1 = 1st intervention (single product use of mCC) * Day 2 = Wash-out * Day 3 = 2nd intervention (single product use of CHTP 1.1 M).

Primary Outcome Measures

Name	Time	Method
Maximum Concentration (Cmax) of Nicotine Following Single Use of CHTP 1.1 M and mCC	Day 3: blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0.	T0 = start of single product use.; Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).; Geometric Least Squares (LS) means are provided.
Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of CHTP 1.1 M and mCC	Day 3: blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0.	T0 = start of single product use.; Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use).; Geometric Least Squares means are provided.

Trial Locations

Locations (1)

Ageo Medical Clinic; 🇯🇵 Saitama, Japan